. 2020 Jun 10;10:848. doi: 10.3389/fonc.2020.00848
Copyright © 2020 Autore, Innocenti, Corrente, Del Principe, Rosati, Falcucci, Fresa, Conte, Limongiello, Renzi, De Padua, Andriani, Pisani, Cimino, Tafuri, Montanaro, Mauro, Del Poeta and Laurenti.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 1.
Progression-free survival in low-risk (LR) patients: bendamustine and rituximab LR vs. chlorambucil-R LR.